Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240161 · ClinicalTrials.gov registry record
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
A clinical trial, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- 37
- Enrollment target
NCT01240161 is a clinical trial that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 37 participants.
The verdict
NCT01240161 has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
Interventions
- DRUG FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-12 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240161
The ClinicalTrials.gov registry entry for NCT01240161 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcelo F. Di Carli, MD, FACC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT is the first listed.
NCT01240161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240161 about?
NCT01240161 is a clinical study titled "Personalized Translational Platform for Biomarker Discovery in Brain Tumors". The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
What is the current status of trial NCT01240161?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2009-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01240161?
The interventions under investigation include: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT (DRUG).
Who is sponsoring clinical trial NCT01240161?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.